Infliximab therapy improves health-related quality of life in patients with psoriatic arthritis - 21/08/11
Dafna Gladman, MD, Toronto Western Hospital, Toronto, ON, Canada; Christian Antoni, MD, Friedrich-Alexander University, Erlangen, Germany; Songkai Yan, PhD, Centcor, Inc., Malvern, PA, United States; Arthur Kavanaugh, MD, University of California, San Diego, La Jolla, CA, United States
Le texte complet de cet article est disponible en PDF. P2769 Dr. Gladman has participated in clinical trials. Dr. Antoni is an investigator and consultant for infliximab for Centocor. Dr. Kavanaugh has consulted and conducted clinical research sponsored by Centocor, Amgen Inc., and Abbott Laboratories. Studies have been funded by research grants from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
Vol 52 - N° 3S
P. P189 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?